-
Sector Analysis
Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032
Non-Alcoholic Steatohepatitis (NASH) Report Overview In the 7MM, there were 22,036,613 diagnosed prevalent cases of NASH in 2022. The market is expected to grow at an AGR of more than 2% during 2022-2032. Non-alcoholic steatohepatitis (NASH) is a subcategory of non-alcoholic fatty liver disease (NAFLD), a condition defined by fat accumulation in over 5% of cells in the liver due to causes other than alcohol consumption (Sharma and John, 2022). NASH is considered to be more severe than the non-alcoholic...
-
Product Insights
Non-Alcoholic Steatohepatitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market Report Overview The Non-Alcoholic Steatohepatitis (NASH) clinical trial market research report provides an overview of the NASH clinical trials scenario. The report provides top-line data relating to the clinical trials on NASH. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.